| Title: |
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity |
| Authors: |
Bognàr, Tim; Garcia-Rosa, Moises; Lalmohamed, Arief; Güngör,Tayfun; Hauri-Hohl,Mathias; Prockop,Susan; Oram,Layne; Pai,Sung Yun; Brooks,Jordan; Savic,Rada M.; Dvorak,Christopher C.; Long-Boyle,Janel R.; Krajinovic,Maja; Bittencourt,Henrique; Teyssier,Anne Charlotte; Théoret,Yves; Martinez,Cary; Egberts, Toine C.G.; Morales,Erin; Slatter,Mary; Cuvelier,Geoffrey D.E.; Chiesa,Robert; Wynn,Robert F.; Coussons,Mary; Cicalese,Maria P.; Ansari,Marc; Long,Susan E.; Ebens,Christen L.; Lust,Hannah; Chaudhury,Sonali; Nath,Christa E.; Shaw,Peter J.; Keogh,Steven J.; van der Stoep,M. Y.C.Eileen; Bredius,Robbert; Lindemans, Caroline A.; Boelens, Jaap Jan; Bartelink,Imke H.; Apotheek O&O&O; Apotheek Klinische Farmacie; Cancer; Infection & Immunity; Apotheek Onderzoek; Regenerative Medicine and Stem Cells; Child Health; SCT patientenzorg |
| Publication Year: |
2024 |
| Subject Terms: |
Hematology |
| Description: |
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment strategy for patients with inborn errors of immunities (IEIs). The objective of this study was to assess the optimal busulfan exposure before allogeneic HCT for patients with an IEI who received an IV busulfan–based conditioning regimen. Patients from 17 international centers were included. The main outcome of interest was event-free survival (EFS). Patients were categorized into 4 IEI subgroups: combined immunodeficiency (CID), severe combined immunodeficiency (SCID), neutrophil disorders, and hemophagocytic lymphohistiocytosis (HLH)–related disorders. Busulfan exposure was calculated by individual centers (area under the curve [AUC]CENTER) and re-estimated using a nonlinear mixed–effects model (NONMEM; exposure defined as AUCNONMEM). Overall, 562 patients were included: 173 (30.8%) with CID, 154 (27.4%) with SCID, 101 (18.0%) with HLH-related disorders, and 134 (23.8%) with neutrophil disorders. The median busulfan AUCNONMEM was 69.0 mg × h/L and correlated poorly with the AUCCENTER (r2 = 0.54). In patients with SCID, HLH-related, and neutrophil disorders with a busulfan AUCNONMEM of 70 to 90 mg × h/L, 2-year EFS was superior to 90 mg ×h/L. Full donor chimerism increased with higher busulfan AUCNONMEM, plateauing at 90 mg × h/L. For patients with CID, the optimal AUCNONMEM for donor chimerism was found to be >70 mg × h/L. Improved EFS and higher donor chimerism may be achieved by targeting a cumulative busulfan AUCNONMEM of 80 mg × h/ L (range, 70-90). |
| Document Type: |
article in journal/newspaper |
| File Description: |
text/plain |
| Language: |
English |
| ISSN: |
2473-9529 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/458702 |
| Availability: |
https://dspace.library.uu.nl/handle/1874/458702 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.DF5CBC54 |
| Database: |
BASE |